Author Correction: BRAF-mutant metastatic NSCLC: disease overview and treatment landscape.
作者信息
Planchard David, Sanborn Rachel E, Negrao Marcelo V, Vaishnavi Aria, Smit Egbert F
机构信息
Thoracic Cancer Group, Department of Medical Oncology, Gustave Roussy, Villejuif, France.
Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
出版信息
NPJ Precis Oncol. 2024 Jul 15;8(1):142. doi: 10.1038/s41698-024-00633-7.
Abstract
摘要
相似文献
1
Author Correction: BRAF-mutant metastatic NSCLC: disease overview and treatment landscape.作者更正：BRAF 突变型转移性非小细胞肺癌：疾病概述与治疗格局
NPJ Precis Oncol. 2024 Jul 15;8(1):142. doi: 10.1038/s41698-024-00633-7.
2
BRAF-mutant metastatic NSCLC: disease overview and treatment landscape.BRAF 突变型转移性非小细胞肺癌：疾病概述与治疗格局
NPJ Precis Oncol. 2024 Apr 16;8(1):90. doi: 10.1038/s41698-024-00552-7.
3
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.达拉非尼联合曲美替尼治疗既往接受过治疗的BRAF（V600E）突变转移性非小细胞肺癌患者：一项开放标签、多中心2期试验。
Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.
4
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.PHAROS 研究的简明报告：encorafenib 和 binimetinib 联合用于治疗携带 BRAF V600E 突变的转移性非小细胞肺癌患者。
Future Oncol. 2024;20(16):1047-1055. doi: 10.2217/fon-2023-0859. Epub 2024 Feb 15.
5
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups.携带突变的转移性非小细胞肺癌多中心观察性研究：聚焦V600E和非V600E亚组的临床特征与治疗结果
Cancers (Basel). 2022 Apr 16;14(8):2019. doi: 10.3390/cancers14082019.
6
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With -Mutant Metastatic Non-Small-Cell Lung Cancer.encorafenib 加 binimetinib 治疗 -mutant 转移性非小细胞肺癌患者的 II 期、开放标签研究。
J Clin Oncol. 2023 Jul 20;41(21):3700-3711. doi: 10.1200/JCO.23.00774. Epub 2023 Jun 4.
7
European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer.欧洲专家小组关于BRAF突变型转移性结直肠癌临床管理的共识
Cancer Treat Rev. 2023 Apr;115:102541. doi: 10.1016/j.ctrv.2023.102541. Epub 2023 Mar 11.
8
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.达拉非尼联合曲美替尼治疗既往未经治疗的 BRAF 突变型转移性非小细胞肺癌的开放标签、2 期临床试验。
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
9
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Mutations.FDA 批准概要：达拉非尼联合曲美替尼治疗携带突变的转移性非小细胞肺癌。
Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642. Epub 2018 Feb 7.
10
Outcomes of non-small cell lung cancer patients with non-V600E mutations: a series of case reports and literature review.非V600E突变的非小细胞肺癌患者的治疗结果：一系列病例报告及文献综述
Front Oncol. 2024 Mar 27;14:1307882. doi: 10.3389/fonc.2024.1307882. eCollection 2024.
引用本文的文献
1
Remarkable Response to Dabrafenib and Trametinib in a V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) V600E-Mutated Lung Adenocarcinoma Patient With Poor Performance Status and Respiratory Failure: A Case Report.达拉非尼和曲美替尼对一名体能状态差且伴有呼吸衰竭的V-Raf鼠肉瘤病毒癌基因同源物B（BRAF）V600E突变肺腺癌患者产生显著反应：一例报告
Cureus. 2024 Dec 6;16(12):e75217. doi: 10.7759/cureus.75217. eCollection 2024 Dec.
Zotero 插件